Drugs

PEER-REVIEWED FEATURE

Nemolizumab: Adis Evaluation

Key Points

- A humanized IL-31RA monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases
- Nemolizumab (Mitchga® Syringes) received its first approval on 28 March 2022 in Japan
- Approved in Japan for use in adults and children over the age of 13 years for the treatment of itch associated with AD (only when existing treatment is insufficiently effective)

Summary

Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody that is being developed by Chugai Pharmaceutical Co. Ltd, Maruho Co. Ltd and Galderma Pharma S.A. for the treatment of skin diseases, including atopic dermatitis (AD), AD associated pruritus (ADaP), prurigo nodularis (PN), chronic kidney disease associated pruritus (CKDaP) and systemic sclerosis (SSc).

IL-31 is a neuroimmune cytokine that induces itch, inflammation, keratinocyte differentiation and fibroblast activation in chronic pruritic skin diseases.

Nemolizumab (Mitchga® Syringes) was approved in Japan on 28 March 2022 for use in adults and children over the age of 13 years for the treatment of itch associated with AD (only when existing treatment is insufficiently effective).

Keam, S.J. Drugs. 2022. https://doi.org/10.1007/s40265-022-01741-z